Cancer Targets and Drug Discovery

癌症靶点和药物发现

基本信息

批准号：
10443758
负责人：
Nicholas David Cosford
金额：
$ 24.66万
依托单位：
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-03 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10443758
关键词：
Malignant Neoplasms drug discovery

项目摘要

T32 Proposal “Cancer Targets and New Drug Discovery” ABSTRACT The goal of the T32 training program “Cancer Targets and New Drug Discovery” is to establish an innovative multi-thematic graduate student and postdoctoral training program (“the Program”) to train the next generation of leaders in cancer target discovery and validation, cancer drug discovery, and biomarker development. This goal will be attained by a 2 year training program for 1 graduate student and 3 postdoctoral trainees, who will be trained in the skills needed to execute a successful cancer drug discovery program using novel paradigms and state-of-the-art technologies. The program uniquely includes a 2-month biotech company internship and training in scientific entrepreneurship specifically focused on new cancer target and drug discovery, as well as research entrepreneurship. The Specific Aims of the Program are: 1) To discover and validate novel cancer drug targets. Training will focus on critically validating new targets in the context of signaling networks, mechanisms of genetic and epi-genetic regulation, and also on exploring non-traditional targets, for example, targeting components of tumor stroma, which is important for supporting cancer cell growth and providing a barrier to attack by immune cells. The genetic stability of the stroma may also render the putative targets less susceptible to developing resistance; 2) To discover small molecule probes to interrogate novel cancer targets. SBP has the technically most advanced and largest chemical library screening program of any academic organization. Our strong expertise in structurally-based rational drug design using NMR and X-ray crystallography will provide training opportunities in probe discovery using both approaches; 3) To conduct mechanistic studies of cancer signaling pathways using probe inhibitors. We will provide training in the use of small molecule probes in cells and preclinical animal models to provide insights into the practical application of drugs to treat cancer, signaling interactions, mechanisms of resistance and potential biomarkers; and 4) To provide entrepreneurial training. Given that fewer than 15% of trainees can expect to have a faculty appointment in academia, we will provide the trainees experience in biopharma research as a possible alternate career. We are located in the second largest hub of biotech companies in the United States, and working with a corporate biotech incubator partner, will provide a unique entrepreneurial T32 training experience with a 2-month cancer biotech internship.

T32提案“癌症靶点和新药发现” 抽象的 T32培训项目“癌症靶点和新药发现”的目标是建立一个创新的多主题研究生和博士后培养计划（“该计划”），以培养下一代癌症靶点发现和验证、癌症药物发现和生物标志物开发领域的领导者。目标将通过为期 2 年的 1 名研究生和 3 名博士后培训生培训计划来实现，他们将接受使用新颖范式成功执行癌症药物发现计划所需的技能培训该计划独特地包括为期 2 个月的生物技术公司实习和培训。科学创业培训特别侧重于新的癌症靶点和药物发现，以及该计划的具体目标是： 1) 发现和验证新型癌症。培训将侧重于在信号网络背景下严格验证新目标，遗传和表观遗传调控机制，以及探索非传统目标，例如，靶向肿瘤基质成分，这对于支持癌细胞生长和提供基质的遗传稳定性也可能使假定的目标减少。 2) 发现小分子探针来研究新的癌症靶点。 SBP 拥有所有学术机构中技术最先进、规模最大的化学库筛选计划我们在使用 NMR 和 X 射线进行基于结构的合理药物设计方面拥有丰富的专业知识。晶体学将提供使用这两种方法进行探针发现的培训机会；使用探针抑制剂进行癌症信号传导途径的机制研究。我们将提供使用探针抑制剂的培训。细胞和临床前动物模型中的小分子探针，为实际应用提供见解治疗癌症、信号相互作用、耐药机制和潜在的生物标志物；以及 4) 鉴于只有不到 15% 的学员可以期望拥有教师。在学术界的任命，我们将尽可能为学员提供生物制药研究的经验我们位于美国第二大生物技术公司中心，并且与企业生物技术孵化器合作伙伴合作，将提供独特的创业T32培训具有为期两个月的癌症生物技术实习经验。